A roadmap for personalized medicine: the findings of the IC2PerMed project

个性化医疗路线图:IC2PerMed项目的研究成果

阅读:2

Abstract

INTRODUCTION: Personalized Medicine (PM) tailors prevention and treatment to individuals based on their unique characteristics. It has the potential to improve health outcomes and healthcare sustainability by optimizing resource allocation. Both the European Union (EU) and China have prioritized PM in their health strategies. The IC2PerMed project was established to foster collaboration between the EU and China by developing a joint PM roadmap. METHODS: To assess the state of PM in the EU and China, the project conducted a comprehensive mapping of relevant policies, programs, funding mechanisms, and health ecosystems. Additionally, three Delphi surveys were carried out, identifying 65 priorities, which were synthesized into a set of strategic actions. RESULTS: The main output of the project is a joint roadmap for implementing PM in the EU and China. The roadmap promotes best practice exchange and addresses potential barriers to PM adoption. It outlines structural actions including enhancing health literacy, fostering intersectoral and international collaboration, ongoing review of emerging technologies, and facilitating innovation market entry through needs assessment and Health Technology Assessment. Key enablers such as data interoperability and shared standards are highlighted, along with ethical, social, and regulatory considerations that are universally relevant to PM implementation. DISCUSSION: A shared action plan can guide health policy and help policymakers understand the interconnection between healthcare, the economy, and society. By supporting international projects and investing in research and innovation, stakeholders can advance global healthcare.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。